Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2 Study of Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)

NCT05640830 is registered in ClinicalTrials.gov with Kangbuk Samsung Hospital as lead sponsor.

NCT NCT05640830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05640830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2 Study of Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)
Lead sponsor
Kangbuk Samsung Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 31, 2026
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive advanced gastric cancer